ClinicalTrials.gg
CompletedNCT03478111Updated Mar 18, 2020

CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis

A Phase 3 interventional study of CMAB008 and MTX in Rheumatoid Arthritis, sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing infliximab in Arthritis, Rheumatoid — 2 open to participants now, 3 under way, 1 of them phase 3. Infliximab · Arthritis, Rheumatoid.

Enrollment
13th of 49
390 · median 172
Started
2018
the only one that year
Phase 3
19 of 49
1 open now
Registered
46th of 49
by date

Among the 49 studies testing infliximab in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is the only one that started in 2018, is one of 19 in phase 3, and was the 46th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 49 studies testing infliximab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing infliximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

CMAB008 is an infliximab biosimilar candidate. The host cell of Remicade is mouse myeloma SP2/0 cell, however, the host cell of CMAB008 is CHO (Chinese hamster ovary cell). It seems that CMAB008 has lower immunogenicity and higher safety, because Remicade comprises more complex-type and hybrid-type glycans than CMAB008. However, it is not yet known whether CMAB008 is not inferior to Remicade. This randomized, double-blind trial investigates the efficacy and safety of CMAB008 for moderately to severely active rheumatoid arthritis, compared to Remicade.

Read the detailed description

This is a non-inferiority trial. The primary outcome is the percentage of subjects achieving ACR20. According to the global instruction of Remicade, the effective rate of Remicade is 50%, and the placebo is 20%. Calculate the critical value δ=(50%-20%)×50%=15%, one-side α=0.025, β=0.20, experimental group : control group = 1:1, the results are: CMAB008 group 175 participants, control group 175 participants, 350 participants in total. Take 10% drop-out into consideration, the finial sample sizes are: CMAB008 group 196 participants, control group 196 participants, 392 participants in total.

During the entire duration of the study, all adverse events (AE) and all serious adverse events (SAEs) are collected, fully investigated and documented in source documents and case report forms (CRF). Study duration encompassed the time from when the participant sign the informed consent until the last protocol-specific procedure has been completed, including a safety follow up period.

This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) as well as all national legal and regulatory requirements.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 years, males or females;
  2. Diagnosis of rheumatoid arthritis according to American College of Rheumatology (ACR) 1987 Revised Criteria for the Classification of Rheumatoid Arthritis, and in moderately to severely active stage during screening;
  3. Have had one or more DMARDs failure (defined as "failure of traditional/conventional DMARD(s) due to lack of efficacy/desired response or side effects" according to 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis);
  4. Non-use of DMARDs (including: Chloroquine, Hydroxychloroquine, Gold Compound, Penicillamine, Salicylazosulfapyridine, Azathioprine, Cyclophosphamide, Cyclosporine A, Leflunomide, Thalidomide etc.) except for MTX in the last 4 weeks before screening;
  5. Have completed at least 3 months of treatment with MTX, and steadily at the dosage of 7.5mg\~15mg/w at least 4 weeks prior to screening;
  6. Non-use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in the last 2 weeks before enrollment, or if using NSAIDs, should stabilize dose at least 2 weeks;
  7. Non-use of (including intramuscular corticotropin) systematically (e.g., oral administration, intramuscular or intravenous injection) or intra-articular injection; or if concurrent taking glucocorticoid orally, dose (equivalent to the dose of Prednisone) should stabilize≤10mg/d at least 4 weeks;
  8. Non-use of Chinese medicine (e.g., Tripterygium, Total Glucosides of Paeony Capsules) for rheumatoid arthritis in the last 4 weeks before screening;
  9. Pregnancy test should be negative for procreative female, or not lactating. Both male and female subjects should consent to take effective throughout the study and at least 6 months after the study;
  10. Signed the form;
  11. Can participate in visits on schedule;
  12. Can understand and complete assessment forms correctly.

Exclusion criteria

Exclusion Criteria:

  1. Weight>75Kg;
  2. Inoculated live (attenuated) viral/bacterial vaccine in the last 4 weeks before screening;
  3. Use of biologicals (including but nor limited to Infliximab, Etanercept, Adalimumab, Tocilizumab, Rituximab etc.) for rheumatoid arthritis in the last 3 months before screening;
  4. Severe infection (e.g., acute hepatitis, pneumonia, acute pyelonephritis) in the last 2 months before enrollment, or previous hospitalization due to infection, or previous use of antibiotics, antifungal or antiviral drugs due to infection. However, low-grade infection (e.g., acute upper respiratory infections, simplex urinary tract infection) is not considered as exclusion criteria, whether the subject can be chosen depends on investigator;
  5. Suffering from acute infection or recurrent infections disease during screening, e.g., respiratory system infection (influenza, upper respiratory infection, bronchiectasia etc.), acute episode of chronic pyelonephritis, infectious skin wound etc,;
  6. Previous opportunistic infection (e.g., herpes zoster, active cytomegalovirus, mycoplasma, pneumocystis pneumonia, histoplasma, aspergillus, mycobacteria except for mycobacterium tuberculosis) in the last 6 months before screening;
  7. History of prosthetic joint infections, or suspicious prosthetic joint infections with antibiotic therapy and unremoved prosthetic joint;
  8. History of severe hepatic diseases; or HbsAg positive; or only HbcAb positive in Second Liver 5 Indexes, and positive; or -infected patient;
  9. AIDS-infected patient or HIVpositive;
  10. One of the following situations relating to tuberculosis:

    1. Concurrent or previous active tuberculosis. Chest X-ray examination (suggest chest anteroposterior and lateral position films) should be performed in the last 3 months before screening, to provide evidence for concurrent or previous tuberculosis;
    2. Intimate contact with active tuberculosis patient recently; or high-risk and/or group (e.g., long-term use of , immunosuppressor), and with any signs of latent tuberculosis infection;
    3. PPD test (inject 5IU TB-PPD intradermally, measure the diameter of skin induration 72 hours later) performed in the last 3 weeks before screening: diameter of induration≤15mm, and with vesicle or necrosis; or diameter of induration>15mm;
    4. If cannot perform PPD test, perform T-SPOT test: T-SPOT test positive, chest file and clinical evidence indicate that the patient is unsuitable for participation;
  11. History of organ allograft operation (except for keratoplasty more than 3 months before the first use of drug);
  12. Concurrent or previous malignant tumor (except for total excision and no recurrence of cutaneous squamous cell carcinoma, basal-cell carcinoma or carcinoma in situ of cervix) in the last 5 years before screening;
  13. History of lymphoid (lymphoma) or lymphoproliferative disease; or symptoms and signs indicate that may be lymphoproliferative disease (e.g., lymph node enlargement at neck, clavicle or axilla) during screening; or splenomegaly (≥subcostal 2cm);
  14. Concurrent or previous demyelinating diseases of the central nervous system (e.g., multiple sclerosis);
  15. Concurrent or previous congestive heart failure;
  16. Concurrent or previous other disease, and may be expected to affect the assessment of investigational drug;
  17. Severe, progressive, uncontrolled cardiovascular, hepatic, renal, pulmonic, gastrointestinal, hematopoietic, endocrine, neural diseases, or other situations that the patient is considered as unsuitable for participation by investigator;
  18. History of severe drug or alcohol abuse with clinical symptoms; history of poor drug compliance; or other situations that may interfere protocol compliance (e.g., mental disease, frequent travel, lack of willingness);
  19. Laboratory tests results meet one of the following indexes: HGB\<8.5g/dL, WBC\<3.5*10\^9/L, \<80*10\^9/L, /AST>2* value, CREA>upper limit of normal value;
  20. Allergic reaction against human immunoglobulin, infliximab or other ingredient;
  21. Participation in another drug clinical trial in the last 30 days before screening or within 5 half-lives of drug (longer time shall prevail).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    CMAB008+MTX

    Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30. Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg\~15mg weekly from Week 0 to 38.

    Drug: CMAB008 · Drug: MTX

  • Active comparator
    Remicade+MTX

    Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30. Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg\~15mg weekly from Week 0 to 38.

    Drug: MTX · Drug: Remicade

Interventions

  • the study drug

    Also known as: infliximab

  • DrugMTX

    basic therapy drug

    Also known as: methotrexate

  • active comparator

    Also known as: infliximab

06

What researchers measure

Primary outcomes

  1. The percentage of subjects achieving ACR20

    Defined as the percentage of subjects achieving ACR20 of all subjects

    Time frame: Baseline up to 30 weeks

Secondary outcomes

  1. The percentage of subjects achieving ACR20

    Defined as the percentage of subjects achieving ACR20 of all subjects

    Time frame: Baseline up to 2,6,14,22 weeks

  2. The percentage of subjects achieving ACR50,70

    Defined as the percentage of subjects achieving ACR50,70 of all subjects

    Time frame: Baseline up to 2,6,14,22,30 weeks

  3. Improvement rate of the duration of morning stiffness

    Improvement rate=(before the treatment - after the treatment)/before the treatment \*100%

    Time frame: Baseline up to 2,6,14,22,30 weeks

  4. Improvement rate of the number of joint swelling or tenderness

    Improvement rate=(before the treatment - after the treatment)/before the treatment \*100%

    Time frame: Baseline up to 2,6,14,22,30 weeks

  5. Improvement rate of Visual Analogue Scale (VAS)

    Improvement rate=(before the treatment - after the treatment)/before the treatment \*100%. Visual Analogue Scale(VAS) is designed to present to the respondent a rating scale. Respondents mark the location on the 10-centimeter line corresponding to the amount of pain they experienced. VAS data of this type is recorded as the number of centimeters from the left of the line with the range 0-10. No pain \<-- 10 cm. --\> Pain as bad as possible

    Time frame: Baseline up to 2,6,14,22,30 weeks

  6. Improvement rate of Health Assessment Questionnaire (HAQ) score

    Improvement rate=(before the treatment - after the treatment)/before the treatment \*100%. The Health Assessment Questionnaire (HAQ) Disability Index assesses a patient's level of functional ability. There are 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The patient's responses are made on a scale from zero (no disability) to three (completely disabled).

    Time frame: Baseline up to 2,6,14,22,30 weeks

  7. Improvement rate of physicochemical indexes of curative effect (ESR, CRP)

    Improvement rate=(before the treatment - after the treatment)/before the treatment \*100%

    Time frame: Baseline up to 2,6,14,22,30 weeks

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jun 2019, 14 months.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 14 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2018
First posted
Mar 27, 2018
StartActual
Mar 30, 2018
Primary completionActual
Jun 23, 2019
CompletionActual
Aug 27, 2019
Last update
Mar 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03478111
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Mar 30, 2018
Primary completion
Jun 23, 2019
Completion
Aug 27, 2019
Last update
Mar 18, 2020

Study contacts

Yin Su, Ph.D
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion